In patients with metabolic-associated steatotic liver disease or metabolic-associated steatohepatitis, resmetirom and ...

The cannabinoid agonist market is gaining momentum due to expanding medical cannabis legalization and growing clinical validation for its use in chro ...

The UK’s drug regulator is to study possible serious side effects of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). Data from ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...